In a study recently published in Nature, Li et al. propose that antibody inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), FDA-approved for hyperlipidemia treatment, have the potential to boost the anticancer efficacy of ICIs.1 The gene discussed is PCSK9; the disease is hyperlipidemia.